Since we have shown that HDAC6 selective inhibitor tubacin significantly enhances bortezomib-induced cytotoxicity in MM cell lines and patient MM cells [14], we examined whether WT161 or other HDAC inhibitors similarly enhanced anti-tumor activity of bortezomib in breast cancer cells. Here, HDAC6 is linked to breast carcinoma.